SFEBES2022 Oral Poster Presentations Reproductive and Neuroendocrinology (4 abstracts)
Background: Hypoactive Sexual Desire Disorder (HSDD) is associated with a deficiency of sexual desire with marked distress. It affects up to 8% of men, but has no licensed treatments. The reproductive neuropeptide kisspeptin offers a putative therapeutic target owing to its emerging role in modulating reproductive behaviour in animal models and healthy men. However, there are no studies examining its effects in HSDD. To address this, we performed the first clinical study of kisspeptin in men with HSDD.
Methods: We examined the effects of kisspeptin administration (vs placebo) on brain activity during short and long erotic video tasks using functional MRI in 32 men with HSDD (mean±
Results: In response to visual erotic stimuli, kisspeptin significantly increased penile tumescence during the long video task compared to placebo, with kisspeptin increasing penile tumescence by 56% (P=0.02). Kisspeptin also increased participant-reported happiness about sex (P=0.02). During both video tasks, kisspeptin significantly modulated brain activity, compared to placebo, in key structures of the sexual-processing network (P<0.05). Additionally, we observed positive correlations between kisspeptins effects on aforementioned brain activity and psychometric parameters of sexual desire and arousal (all P<0.01).
Conclusion: Collectively, we demonstrate for the first time that kisspeptin in men with HSDD increases penile tumescence and psychometric measures of sexual desire and arousal by modulating sexual brain processing. Our data suggest that kisspeptin-based therapeutics may offer a novel, effective and much-needed clinical strategy for men with HSDD.
14 Nov 2022 - 16 Nov 2022